Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › enfortumab vedotin

enfortumab vedotin

5 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of enfortumab vedotin

3 trials tracked of enfortumab vedotin: 1 in phase 3 or 4 and 1 with published results. The most-cited published study has 1239 citations.

3Trials tracked
1Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 3 1 Phase 2 2
  1. Phase 3 A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301) Completed · 1,239 cited
  2. Phase 2 A Study to Evaluate Enfortumab Vedotin (ASG-22CE) in Chinese Participants With Locally Advanced or Metastatic Urothelial Cancer Who Previously Received Platinum-containing Chemotherapy and Programmed Cell Death Protein-1 ( PD 1) / (Programmed Death Ligand-1 (PD-L1) Inhibitor Therapy Completed
  3. Phase 2 A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer Completed

Showing the 3 most-cited and recently-updated of 3 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Multimodal imaging clarifies cardiac mass in sarcomatoid urethral carcinoma despite relentless locoregional progression
Pulmonology & Critical Care Sys. Review
Multimodal imaging clarifies cardiac mass in sarcomatoid urethral carcinoma despite relentless locoregional progression Multimodal Imaging Helps Detect Heart Issues in Rare Urethral Cancer
This case report and literature review describes a 54-year-old man with cT4N0M0 sarcomatoid urothelial carcinoma of the bulbar urethra treat…
A single case report highlights how advanced imaging can identify heart and lung issues in patients with rare types of urethral cancer.
Frontiers Oct 22, 2026
Enfortumab vedotin cutaneous toxicity and peripheral neuropathy are associated with improved outcomes in urothelial carcinoma
Urology Meta-analysis
Enfortumab vedotin cutaneous toxicity and peripheral neuropathy are associated with improved outcomes in urothelial carcinoma Skin Reactions and Nerve Issues Linked to Better Survival
This meta-analysis evaluates the association between enfortumab vedotin-related adverse events and clinical outcomes in patients with advanc…
A review of patients with advanced urothelial carcinoma suggests that certain side effects from enfortumab vedotin may link to improved surv…
Oct 4, 2026
Females with advanced bladder cancer show significantly better progression-free survival on enfortumab vedotin
Urology Meta-analysis
Females with advanced bladder cancer show significantly better progression-free survival on enfortumab vedotin Women with bladder cancer show better outcomes on specific treatment
This meta-analysis of 17 studies evaluated sex-specific outcomes for patients with advanced or metastatic urothelial cancer treated with enf…
Women with advanced bladder cancer may experience longer periods without disease progression when treated with enfortumab vedotin.
Oct 4, 2026
Phase 3 RCT Shows Perioperative Enfortumab Vedotin and Pembrolizumab Benefit Muscle-Invasive Bladder Cancer
Drug Pipeline RCT
Phase 3 RCT Shows Perioperative Enfortumab Vedotin and Pembrolizumab Benefit Muscle-Invasive Bladder Cancer New Hope for Bladder Cancer Patients Who Can’t Tolerate Standard Chemo
This phase 3 randomized controlled trial enrolled 344 patients with muscle-invasive bladder cancer ineligible for cisplatin-based chemothera…
A new two-drug treatment more than doubles the odds of staying cancer-free for bladder cancer patients who can't handle standard chemo.
Apr 18, 2026
Systematic review of 2025 RCTs identifies new standards of care across genitourinary cancers
Diabetes & Endocrinology Meta-analysis
Systematic review of 2025 RCTs identifies new standards of care across genitourinary cancers New standards of care established for bladder, kidney, prostate, testicular, and penile cancers in 2025
A systematic review and meta-analysis of 40 phase II/III RCTs in patients with bladder, kidney, prostate, testicular, and penile cancers fou…
New 2025 standards of care for bladder, kidney, prostate, testicular, and penile cancers now emphasize biomarker-driven strategies and immun…
Frontiers Apr 9, 2026